Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations

Matsumoto, Tomohiro; Endo, Jun; Hashida, Kazunobu; Ichikawa, Hitoshi; Kojima, Seiichiro; Takashimizu, Shinji; Watanabe, Norihito; Yamagami, Takuji; Hasebe, Terumitsu

doi:10.3109/13645706.2014.951657

Cited by 32 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matsumoto et al . described a 1.8‐Fr tip microballoon catheter enables selective catheterization in patients with HCC and B‐TACE using the 1.8‐Fr tip microballoon catheter is a safe procedure …”

Section: Discussionmentioning

confidence: 99%

“…Matsumoto et al described a 1.8-Fr tip microballoon catheter enables selective catheterization in patients with HCC and B-TACE using the 1.8-Fr tip microballoon catheter is a safe procedure. 36 Miriplatin is an anticancer agent that produces less vascular disease including narrowing vessels and shunt formation and only transiently remains in vessels surrounding tumor vessels, and thus has no major side-effects. [37][38][39] No significant change in surrounding vessels was found in retreatment after C-TACE ( Fig.…”

Section: Any Patients With Hcc Have Hepatic Cirrhosismentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Ogawa¹,

Takayasu²,

Hirayama³

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

Aim:The goal of the study was to evaluate the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma (HCC) using miriplatin (a lipophilic anticancer drug) and gelatin particles.Methods: B-TACE was performed for 62 HCC nodules in 33 patients who could not be treated by surgical resection or radiofrequency ablation. All 33 patients had a history of transarterial chemoembolization (TACE) treatment prior to B-TACE. As a historical comparison, we investigated 40 nodules in 28 patients treated by TACE using a conventional microcatheter (C-TACE), miriplatin and gelatin particles. The therapeutic effect per tumor was compared between the groups based on the Response Evaluation Criteria in Cancer Study Group of Japan (RECICL) and side-effects were compared based on the Common Terminology Criteria for Adverse Events (ver. 4.0). Results:The therapeutic efficacy after 4-12 weeks was evaluated in 59 nodules in the B-TACE group and in 37 nodules in the C-TACE group. Of these nodules, TE4 occurred in 29 (49.2%) in the B-TACE group and in 10 (27%) in the C-TACE group. Local efficacy was significantly higher in nodules treated by B-TACE than by C-TACE. The side-effects on hepatic function were similar in the two groups. Conclusion:Our results suggest that B-TACE with miriplatin is a useful treatment for hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Any Patients With Hcc Have Hepatic Cirrhosismentioning

confidence: 99%

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Ogawa¹,

Takayasu²,

Hirayama³

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…The evolution of microballoons have enabled various procedures such as balloon-occluded transarterial chemoembolization for hepatocellular carcinoma (Lucatelli et al, 2019;Matsumoto et al, 2015;Matsumoto et al, 2016;Matsumoto et al, 2017), balloon-occluded retrograde transvenous obliteration for gastric varices (Mine et al, 2017), and coaxial microballoon-occluded coil embolization for vascular disorders (Yasumoto et al, 2015). The present study shows, for the first time, the effectiveness and safety of TAE using a 1.8-Fr tip microballoon catheter with a mixture of ethanol and Lipiodol in the treatment of unruptured renal AML.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter arterial embolization for unruptured renal angiomyolipoma using a 1.8-Fr tip microballoon catheter with a mixture of ethanol and Lipiodol

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: To evaluate the efficacy and safety of transcatheter arterial embolization for renal angiomyolipoma using a 1.8-French tip microballoon catheter and a mixture of ethanol and Lipiodol. Methods: Seven consecutive patients with total of eight angiomyolipomas underwent this procedure between June 2014 and June 2017. A 1.8-French tip microballoon catheter was advanced to the feeding artery of the angiomyolipoma, and transcatheter arterial embolization was performed with a mixture of ethanol and Lipiodol under microballoon inflation. We retrospectively evaluated the characteristics of angiomyolipomas, technical success rate, clinical success rate, renal function, and adverse events. Technical success and clinical success were defined as complete embolization of all feeding arteries and reduction of tumor size, respectively. Results: The median size of the angiomyolipomas was 46 mm (range, 40-64 mm). Transcatheter arterial embolization was successful in all eight angiomyolipomas. The median volume of the mixture of ethanol and Lipiodol was 6.0 ml (range, 2.0-14 ml). The median ratio of ethanol to Lipiodol was 71% (range, 71-75%). All eight angiomyolipomas shrank with a median shrinkage rate of 34% in diameter (range, 9-63%) and 77% in volume (range, 48-94%). The median follow-up period was 13 months (range, 9-54 months). Clinical success was achieved in all cases. Serum creatinine concentrations and the pre-and post-procedural estimated glomerular filtration rates did not change notably, and there were no major complications. Conclusion: Transcatheter arterial embolization for renal angiomyolipoma using a 1.8-French tip microballoon catheter with a mixture of ethanol and Lipiodol is effective and safe.

show abstract

“…consequence, the current procedures demonstrated insufficient deposition results close to the tumor vessels promoting tumor growth. Furthermore, some therapeutic agents end up in the systemic flow, and destroy healthy liver tissue via ischemia, radiation damage and/or drug inflammation [7], [8] .…”

Section: Microvascular Networkmentioning

confidence: 99%

Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles for Liver Cancer

Mellal

Folio

Belharet

et al. 2016

IEEE Trans.on Nanobioscience

View full text Add to dashboard Cite

To enhance locoregional therapies for liver cancer treatment, we propose in this study a mathematical model to optimize the transcatheter arterial delivery of therapeutical agents. To maximize the effect of the treatment and minimize adverse effects on the patient, different mathematical models of the tumor growth are considered in this study to find the optimal number of the therapeutic drug-loaded magnetic nanoparticles to be administered. Three types of therapy models are considered, e.g., angiogenesis inhibition therapy, chemotherapy and radiotherapy. We use state-dependent Riccati equations (SDRE) as an optimal control methodology framework to the Hahnfeldt's tumor growth formulation. Based on this, design optimal rules are derived for each therapy to reduce the growth of a tumor through the administration of appropriate dose of antiangiogenic, radio- and chemo-therapeutic agents. Simulation results demonstrate the validity of the proposed optimal delivery approach, leading to reduced intervention time, low drug administration rates and optimal targeted delivery.

show abstract

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations

Abstract: A 1.8-Fr tip microballoon catheter enables selective catheterization in patients with HCC and B-TACE using the 1.8-Fr tip microballoon catheter is a safe procedure.

Cited by 32 publications

References 16 publications

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Transcatheter arterial embolization for unruptured renal angiomyolipoma using a 1.8-Fr tip microballoon catheter with a mixture of ethanol and Lipiodol

Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles for Liver Cancer

Contact Info

Product

Resources

About